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People who use drugs
Northern New England
Opioid initiation
A B S T R A C T
Background: In rural northern New England, located in the northeastern United States, the overdose epidemic
has accelerated with the introduction of fentanyl. Opioid initiation and transition to opioid injection have been
studied in urban settings. Little is known about opioid initiation and transition to injection drug use in rural
northern New England.
Methods: This mixed-methods study characterized opioid use and drug injection in 11 rural counties in
Massachusetts, Vermont, and New Hampshire between 2018 and 2019. People who use drugs completed audio
computer-assisted self-interview surveys on substance use and risk behaviors (n = 589) and shared personal
narratives through in-depth interviews (n = 22). The objective of the current study is to describe initiation of
opioid use and drug injection in rural northern New England.
Results: Median age of first injection was 22 years (interquartile range 18–28 years). Key themes from in-depth
interviews that led to initiating drug injection included normalization of drug use in families and communities,
experiencing trauma, and abrupt discontinuation of an opioid prescription. Other factors that led to a transition
to injecting included lower cost, increased effect/ rush, greater availability of heroin/ fentanyl, and faster relief
of withdrawal symptoms with injection.
Conclusions: Trauma, normalization of drug use, over-prescribing of opioids, and abrupt discontinuation chal-
lenge people who use drugs in rural northern New England communities. Inadequate opioid tapering may in-
crease transition to non-prescribed drug use. The extent and severity of traumatic experiences described high-
lights the importance of enhancing trauma-informed care in rural areas.
1. Introduction
Opioid use and misuse are a major public health problem in rural
areas of the United States (Han et al., 2015). Non-prescription opioid
use and overdose deaths have increased significantly in rural regions of
the Northeast, the Midwest, and Appalachia (Brady et al., 2015;
Kolodny et al., 2015; Paulozzi et al., 2015). In rural northern New
England, the introduction of fentanyl accelerated the opioid epidemic
(Somerville et al., 2017). Hepatitis C virus (HCV) rates (Stopka et al.,
2017, 2019a,b) and other comorbidities of drug injection, including
infectious endocarditis and osteomyelitis (Wurcel et al., 2016, 2018),
have similarly increased.
Previous research on opioid initiation and transition to injection has
primarily been conducted in urban settings (Lankenau et al., 2012;
Mars et al., 2014), and has implicated experiences with trauma and
family history of substance use as causative factors (Lawson et al.,
2013; Sansone et al., 2009; Taplin et al., 2014). However, the risk en-
vironment for opioid initiation and transition to injection in urban
settings may meaningfully differ from the risk environment in rural
settings. The risk environment framework developed by Rhodes (2002)
proposes that four types of environmental factors - physical, social,
economic, and policy - work together to influence the risk of drug-re-
lated harms. Subsequent work examining the overdose risk environ-
ment added health services and criminal justice interventions as
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additional environmental factors (Fadenelli et al., 2019). These factors
operate at both micro and macro levels. Research has already high-
lighted some differences between urban and rural risk environments,
showing that rural communities suffer a disproportionate burden of
opioid misuse and have limited access to substance use treatment (Oser
et al., 2011; Palombi et al., 2018). However, very little research has
explored the rural risk environment for opioid initiation and transition
to injection. Qualitative research in rural Appalachia found that pre-
scription opioids were widely used, and the transition from non-injec-
tion to injection drug use followed, on average, three years after in-
itiation (Draus and Carlson, 2006; Young and Havens, 2012). However,
little is known about opioid initiation and transition to injection drug
use in rural northern New England, a region which has experienced
similarly high rates of opioid use disorder (OUD) and related co-
morbidities.
The goal of the current study was to assess the risk environment for
opioid initiation and transition to injection among people who use
drugs (PWUD) in rural northern New England. We employed mixed
methods, between 2018 and 2019, in rural communities of
Massachusetts, Vermont, and New Hampshire.
2. Materials and methods
The Drug Injection Surveillance and Care Enhancement for Rural
Northern New England (DISCERNNE) study characterized opioid use
and drug injection in 11 rural counties abutting the Connecticut River
Valley in Massachusetts, Vermont, and New Hampshire (Fig. 1) using
mixed methods (Cresswell and Plano Clark, 2017). The study included
an epidemiologic, policy, and legal scan (Stopka et al., 2019a,b); in-
depth qualitative interviews with stakeholders (n = 31) and PWUDs (n
= 22); audio-computer assisted self-interviews (ACASI) with PWUDs,
with a focus on risk environment measures and behavioral risks (e.g.,
sociodemographic, substance use, and social network characteristics) (n
= 589); and HIV, HCV, and syphilis testing among ACASI participants.
The current mixed-methods study analyzes data from our in-depth in-
terviews (n = 22) and ACASIs (n = 589) with PWUD to explore in-
itiation of opioid use and drug injection in rural northern New England.
2.1. Recruitment
Recruitment was conducted at 11 study sites selected in consulta-
tion with local public health officials and service providers. Field staff
recruited 51 seeds through street outreach and at harm reduction
agencies, and 538 participants were referred to the study through re-
spondent driven sampling methods. Participants eligible for the ACASI
were at least 18 years old, spent more than half of the past 30 days
living in the study area, used opioids “to get high” or injected any drug
in the past 30 days, and were able to provide informed consent. We
sought to obtain an in-depth interview sample reflective of the larger
PWUD community by sex, age, and opioid use patterns. The qualitative
sample was recruited at the same time and in the same locations as the
ACASI sample using purposive sampling approaches to reach a wide
variety of participants with injection experience. In addition to the
ACASI inclusion criteria, eligibility to participate in the in-depth in-
terviews also included people who injected in the past year, but not in
the past month. The (BLINDED)Baystate Health Institutional Review
Board approved study protocols (IRB#: 1094092-30). All study records
were confidential and securely stored. Documentation that contained
identifying information (consent form, locator form, receipt) were
stored separately from survey and interview data. To protect con-
fidentiality, participants were assigned a study ID number. Pseudonyms
were assigned to refer to each in-depth interview participant.
2.2. ACASI survey
Survey participants completed a 90-minute audio computer-assisted
self-interview (ACASI) survey (n = 589). Use of an ACASI increases
accurate reporting of substance use and other sensitive behaviors as it
allows participants privacy in responding and has greater perceived
confidentiality than other survey methods (Gribble et al., 2000; Simoes
et al., 2006). The ACASI collected information on the participants’ so-
ciodemographic characteristics, substance use patterns, risk behaviors,
and substance use treatment engagement, such as self-help groups,
outpatient counseling, residential treatment, detox, sober house, and
MOUD. PDF, TJS, and ALD led ACASI data collection, and LMK and ER
were in the field. The quantitative analysis about age of first injection in
this paper focuses on participants who reported they had injected in the
last 30 days and answered the question about age of first injection (n =
417). We also present results for questions on age at first injection and
demographic characteristics (age, gender, state of residence, and cur-
rent MOUD treatment). Survey recruitment occurred between May
2018 and October 2019. Participants received $40 upon completing
ACASI and infectious disease assessment.
2.3. In-depth interviews
Four interviewers (TJS, LMK, ER, and PDF) conducted twenty-two
semi-structured in-depth key informant interviews with PWUD. Of the
22 participants interviewed, 16 also participated in the ACASI survey.
Participants engaged in 45−90 minute audio-recorded interviews to
provide an understanding of both micro and macro dimensions of risk
environments related to the opioid epidemic. The interview guide ex-
plored personal narratives focused on: 1) substance use; 2) injection
drug use; and 3) overdose. LMK transcribed recordings for analysis.
Interview recruitment occurred between April 2018 and August 2019.
Participants received $25 upon completing an in-depth interview.
Fig. 1. Drug Injection Surveillance and Care Enhancement for Rural Northern
New England (DISCERNNE) Study Counties, 2018-2019.
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An interdisciplinary team with expertise in public health, medicine,
nursing, addictions, and epidemiology collaborated using an estab-
lished thematic analysis strategy (Braun and Clarke, 2012). Team
members initially independently coded three interview transcripts and
met weekly to reach consensus on coding structure and process. Two
team members coded each subsequent transcript in Dedoose version 8
(SocioCultural Research Consultants, 2018) and achieved consensus
through triangulation of observations. For the current study, final
analyses were guided by the risk environment framework and focused
on text segments tied to the following codes: initiation and drug transi-
tion/pathway; parent/caregiver substance use; family; community changes;
precipitating event; trauma/mental health; opioid prescription abruptly dis-
continued; and pain management. A community engagement studio
(Joosten et al., 2015) was held to present findings to a group of PWUD,
elicit feedback, and validate findings. This provided a more reflective
understanding of the initial findings to guide analysis. PWUD strongly
endorsed the preliminary themes and subthemes presented here and
provided additional suggestions for future analyses.
3. Results
In-depth qualitative interview participants (n = 22) and the ACASI
quantitative sample (n = 589) generally shared demographic char-
acteristics (Table 1). From the ACASI, a majority of participants re-
ported heroin as their drug of choice (n = 351, 60 %) followed by
cocaine/ crack (n = 95, 16 %), opiate pain killers (n = 44, 7 %), bu-
prenorphine (n = 25, 4%), street fentanyl (n = 23, 4%), and me-
thamphetamine (n = 23, 4 %). Among participants currently injecting
drugs (n = 453), the drugs most commonly injected in the past 30 days
included heroin (n = 395, 87 %), street fentanyl (n = 267, 59 %),
cocaine/crack (n = 227, 50 %), speedball (heroin and cocaine) or
screwball (heroin and methamphetamine) (n = 148, 33 %), opiate pain
killers (n = 116, 26 %), methamphetamine (n = 115, 25 %), and
buprenorphine (n = 115, 25 %). The qualitative interview sample was
nearly equally split between males (n = 10) and females (n = 12), with
ages ranging from 23-55 years. Table 2 features characteristics of in-
depth interview participants related to qualitative themes of their ex-
periences. Half (n = 11) of interview participants first used opioids
between 10–17 years old (Table 2), either medically prescribed or non-
medically. Only two (9.1 %) initiated opioid use after age 25. The
majority of in-depth interview participants had histories of family drug
use (n = 20, 90.1 %), histories of trauma (n = 20, 90.1 %), and were
prescribed opioids early in their opioid use experience (n = 12, 54.5 %)
(Table 2).
3.1. Pathways to injection: themes from qualitative in-depth interviews
Normalization of drug use, experiencing trauma, having pain, and
having their opioid prescription abruptly discontinued were key fea-
tures of the risk environment for transition to injection drug use
(Fig. 2). These themes represent commonalities across interviews, al-
though no single pathway to injection was described.
3.1.1. Normalization of drug use within the family and community
Normalization of drug use within the family and community was an
important feature of the micro-social environment. Every interview
participant (n = 22, 100 %) reported normalization of drug use within
the family or community as being influential in opioid initiation or
injection (Fig. 2). Normalization within the family included awareness
of drug use by parents or other family members. Initiation tied to family
norms included family members providing opioids or other drugs at an
early age. Mike (a 28-year-old male [28 yo M]) said:
I got really close to my older sister. She was like 10 years older than me. I
moved in with her… when I was 12 years old and, because we were really
close… it was like going from not being exposed to anything in the world to
getting exposed to everything all at once. I started, I had probably every drug
my sister had ever done when I was there experimented by the age of 13. So,
it was non-stop. It was crazy.
Being provided drugs early in adolescence was often connected to
progressive use including later transitions to injecting.
Table 1
Characteristics of DISCERNNE In-Depth Interview and ACASI Survey Study







% N % N
Age
18−25 13.6 3 14.8 87
26−39 72.7 16 53 312
40 and older 13.6 3 32.3 190
Race: White 90.3 532
Ethnicity: Non-Hispanic 95.2 561
Gender: Female 54.5 12 41.3 243
State
New Hampshire 31.8 7 33.8 199
Vermont 50 11 52.3 308
Massachusetts 18.2 2 13.9 82
Ever Injected 95.4 21 84.7 499
Age at Injection Initiationa
10−13 0 0 4.6 19
14−17 16.7 2 18.9 79
18−25 50 6 43.7 182
26−39 33.3 4 26.1 109
40 and older 0 0 6.7 28
Currently Injecting (past 30
days)




54.5 12 33.8 199
DISCERNNE = Drug Injection Surveillance and Care Enhancement for Rural Northern
New England, ACASI = audio computer-assisted self-interviews, MOUD =
medication for opioid use disorder
a age at injection initiation is for injection of any substance: in-depth inter-
view participants were not directly asked age and 8 interview participants did
not describe within interviews, percentage based on number of responses (N =
12). Survey assessed age of injection initiation for those that had injected in the
last 30 days, 36 respondents were missing data, (N = 417).
Table 2
Opioid Use Initiation Characteristics of In-Depth Interview Study Participants in










40 and older 9.5 2
History of Family Drug Use 90.1 20
History of Traumab 90.1 20
Prescribed Opioids for Medical Issues 54.5 12
Years Injecting Drugsc
0−4 years 23.5 4
5- 9 years 11.7 2
10 or more years 35.3 6
a for age at first opioid use, 1 participant did not indicate age, percentage
based on number of responses (N = 21).
b history of trauma was tabulated from any mention of physical, sexual, or
emotional trauma within interviews (N = 21).
c years injecting percentages based on those currently injecting (N = 17),
missing age at initiation of injecting for 5 participants.
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Even when opioids were not used within the family, growing up
around alcohol and cannabis desensitized interviewees to opioids.
Jessica (32 yo F) described that:
There was drug use and alcoholism in my family… it had a huge im-
pact… it was normal you know, to go into my mom’s top drawer and grab
her bag of weed for her.
Access to substances through a family member was a key to initia-
tion. Ashley (28 yo F) was not interested in opioids early on, but began
stealing prescriptions:
I started smoking pot when I was 8½-years-old. Um, that later led to
stealing my dad’s… Percocet and trading them for my weed. I didn’t know
what they were, I just knew someone liked them.
Ashley also described being caught stealing pills and her father
“wanting to be cut into the deal.”
Drug use was accepted in the communities of interviewees, creating
a micro-social environment that was characterized by easy access, drug
houses, and open use. “Everybody uses drugs” was a common refrain.
Participants mentioned that “three fourths of people in town use (Mike,
28 yo M),” “people who don’t do drugs are the exception (Amanda, 29
yo F),” “everybody’s becoming a drug dealer these days it seems (Matt,
24 yo M),” and you “can’t walk 20 feet down the street without finding
someone you can get drugs from (Sarah, 28 yo F).” Some connected the
ubiquity to high rates of opioid prescribing. As Jacob (24 yo M) de-
scribed, “two of the biggest pill pushers in the state [are here].”
3.1.2. Trauma
Exposure to trauma was a ubiquitous feature of the micro-physical
environment. Twenty of the 22 participants described experiencing
some type of trauma. Trauma consistently influenced opioid initiation,
escalation of use, and transition to injection. Traumatic events included
deaths of loved ones by suicide or overdose, incarcerations, sexual
abuse, violent crime, rape, homelessness, divorce, foster care place-
ment, custody loss, and miscarriage. Chris (29 yo M) said:
I had a lot of pain growing up… I had lost one friend to a drug overdose.
I was, uh, 16. He took, uh, a bunch of OxyContin, like a whole bottle of it.
Like on purpose… (when) I grew up there was a lot of death around. There
was a lot of drugs and the drugs, you know, blocked out the pain. So all my
friends used so I did too, you know. My friend comes up and says here try
this. It makes me feel better. I’m like all right.
Substance use was also a coping mechanism for trauma as Emily (23
yo F) described:
My mom and dad got divorced about when I was 10. I am the one that
took it the worst, so when I started drinking, smoking weed, smoking ci-
garettes. Just acting out… that all happened until I was about 15. Then I got
my first like actual serious relationships, and I was with this kid for almost
six years. And that’s when I first tried heroin and coke together, so I was
speedballing most of the time. That’s what I’ve always done with it. But just
the divorce really fucked me up…
Traumatic experiences also influenced escalation of drug use.
Compounded trauma was frequent, as when Matt (24 yo M) experi-
enced the stillbirth of his child, a death, and a suicide within a year
(Fig. 2). In his words, “I’ve never confronted my emotions… as soon as I
lost my baby, I went, dove headfirst into the drugs to just mask everything, to
just not feel anything.” Additional events that led to escalation included
death of a mother, father, sister, or close friend and depressive states.
Mike’s (28 yo M) substance use escalated after the loss of his mother:
Once she [my mother] died I tried to kill myself. Like I was buying, I was
doing double, triple of what I normally would do… I just never left my
apartment. I… had all my dealers just come stay at my house. I wouldn’t
want to leave my place, nothing, just wanted to stay in my room, blinds
down, and just get high all the time.
Similarly, snorting opioids no longer alleviated Brittany’s (28 yo F)
dysphoria after she lost custody of her children:
I was lonely. I was depressed. I didn’t have my kids. My man was in
jail… I snorted a bag of dope. I didn’t feel it. That pissed me off. So then I got
another bag… I had needles. I got my own. And that’s when I took a half a
bag of dope… that’s when I first injected… I put a tie on my arm, and like it
took me a little bit to find a vein because I had never done it before…
When experiencing depressive feelings, injecting often became an
efficient way to get relief.
Fig. 2. Thematic analysis of opioid use initiation and transition to injection drug use among people with recent opioid use or injection drug use history in rural
Vermont, New Hampshire and Massachusetts, 2018-2019 (N = 22).
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3.1.3. Abrupt discontinuation of opioid prescriptions
Of the 22 participants, twelve described receiving prescription
opioids after an accident, injury, or illness; two-thirds of these reported
that their provider’s abrupt discontinuation of their opioid prescription
influenced their transition to non-prescribed opioids. Matt (24 yo M)
had some exposure to opioids before receiving a prescription:
I was smoking marijuana, and people I was around doing that had some
Percocet, asked if I wanted to snort some, and ‘Sure! I’ll try that.’ And it was
an every once in a while thing. And then I got into a car accident and, uh, hit
my head on the windshield really hard and was prescribed Vicodin. And I
started taking them as prescribed and then just started abusing them. And,
uh, it just got out of control pretty quick.
Relatively easy access to prescription opioids was an important
component of the micro-social environment. Regardless of duration, the
experience of using prescription opioids was implicated in experi-
mentation and transitions to non-prescribed opioids. Experiencing relief
or euphoria later led to seeking out opioids. As Lisa (51 yo F) described:
My first significant memory [of using opioids] is when I had my wisdom
teeth out. I believe I was about 19 at the time… That’s when I realized okay,
I like this… I remember very specifically I, just feeling wonderful in my
mom’s recliner.
Although Lisa’s regular use of opioids occurred after multiple
traumatic events, this early memory of relief led her to seek out opioids
to cope with pain and depression. Decreasing availability and doses of
prescribed opioids were common. For example, Lisa initially received
“90 morphine [pills] with three refills” after a complicated wisdom
tooth removal. Many were treated with opioids for chronic pain and
then suddenly experienced abrupt discontinuation of opioid prescrip-
tions leading to a transition to non-prescription opioid use. This sudden
change in opioid prescribing practices was an important feature of the
micro-health services/ criminal justice intervention environment.
Jessica (32 yo F) had her opioid prescription abruptly stopped by her
clinician (Fig. 2) and was surprised to experience withdrawal. She re-
ported she was then advised to “go to rehab” where she learned “you
could get cheaper drugs.” She lost custody of her child when she went
to treatment, and opioids helped her cope.
Similar to other participants, Josh (30 yo M) felt forced to use
heroin for pain management when his prescriber abruptly discontinued
his opioid prescription:
Honestly I actually fucking hated and despised myself that I even swit-
ched to it, but can’t deal with the fucking pain and function at work and
get all the shit done that I need to without something for the pain, so I’m kind
of caught in this god damn cycle of I need something for the pain so I can
support myself and my family. But I really don’t want to be on heroin, but I
can’t get the prescription pills back because they don’t see me as a case that
actually needs them.
Josh felt that he was mislabeled as an “addict” instead of someone
forced to use heroin for pain.
3.2. Transition to injection drug use
Among the PWUD who participated in the ACASI survey, the
median age of first injection was 22 years (range 10–60; interquartile
range 18–28 years). Age at injection initiation is depicted in a “age at
event curve” (Fig. 3) overlaid with case summaries from four in-depth
interviews with PWUD. The quantitative survey estimates age of first
injection in a larger sample of people who have injected in the past 30
days (n = 417) from rural northern New England, and the four nar-
ratives suggest overlapping pathways to injection consistent with
opioid initiation and injection transition themes. The reported timing of
injection initiation is similar in our quantitative and qualitative ana-
lyses. From the shape of Fig. 3, injecting typically begins between the
late teens and mid-30 s in this rural sample, with a smaller group of
ACASI participants initiating injection before the teen years or after age
40.
In addition to normalization, trauma, pain, and abrupt
discontinuation of opioid prescriptions, other contextual factors tied to
the transition to injection included: lower cost, increased effect/rush,
greater availability of heroin/ fentanyl, and faster relief of withdrawal
symptoms. James (47 yo M) and others were leery of injecting at first:
She's like, ‘you can't do it that way [James].’… for the cost and how
quick you can get better, you know… (I thought) ‘Jesus, [James], what are
you doing… but I mean I was sick. The mind’s set just to get over being sick. I
mean come on man. I can't, I'm freezing, I'm cold, I'm sneezing, my whole
body aches. What is this gonna do? I'm hurting. And then woosh. She in-
jected me with it, and within 20 s I was like ‘wooo hooo.’ I feel so much
better. Oh my God… I had extra energy.
These sensations led James to transition solely to injecting. Cost was
also a factor for him:
How much did that cost us?… Like $10 a day, that's it? I can come up
with $10 a day. Ten dollars for you, $10, $20 a day, we could do that. It
wasn't $20 a day within a month. We were up to 70, 80 bucks a day, you
know?… I'd been addicted to it since.
As the street supplies of diverted prescription opioids decreased and
costs rose, injecting was cost efficient and provided immediate relief.
This change in the supply and cost of prescription opioids relative to
heroin/fentanyl was an important feature of the micro-economic en-
vironment.
The greater effect or rush led many to stop swallowing or snorting.
Dan (29 yo M) had been snorting opioids but tolerance led him to inject:
Well anyway my best friend started saying to me, he’s like… you really
want to feel it, because I wasn’t really getting what I wanted… from snorting
it… He did it all up for me, put it in a spoon, did it, cooked it, everything, put
it into the syringe, hit me with it… I felt it like crazy… So that’s when I
started buying Oxycontins like regularly more than I was supposed to but not
really spending as much money.
Participants consistently described their first injection of an opioid
as vivid and remarkable, and the majority continued injecting.
4. Discussion
This mixed-methods study presents novel findings on the risk en-
vironment for opioid use initiation and transition to injecting in rural
northern New England between 2018 and 2019. Key features of the
rural risk environment included: normalization of drug use in families
and communities, opioid initiation and escalation related to trauma,
and abrupt discontinuation of opioid prescriptions by their clinician.
Both separately and together, these three features of the risk environ-
ment were most salient to opioid initiation and the transition to in-
jection among rural PWUDs.
Normalization of drug use and misuse was prevalent during first use
of drugs, with the majority of participants connecting initial use to
drugs from their or a friend’s parent. Drugs were often diverted from or
offered by family members. Previous research has similarly described
the influence of family and peer groups in pathways toward injection
(Parolin et al., 2016; Taplin et al., 2014), but have not as explicitly
identified community-wide norms as important features of the micro-
social risk environment in rural areas. Although peer group norms have
previously been described, our analysis of initiation demonstrated more
reference to broader contexts of norms such as community or town.
Exposure to trauma was nearly universal among our participants.
Trauma, including domestic violence, sexual abuse, loss of family or
friends, serious accidents, and loss of custody, permeated their lives.
Most participants in these rural counties recounted traumatic experi-
ences as they explained their transition to injection drug use. Previous
urban studies have focused on associations between trauma and opioid
use initiation (Sansone et al., 2009; Taplin et al., 2014), and qualitative
analyses have found that social context and interactions are associated
with injection initiation (Guise et al., 2017). Maternal alcohol and drug
use has been associated with childhood trauma among people who
inject drugs, which in turn is associated with earlier age at injection
(McGovern et al., 2018; Taplin et al., 2014). Our results extend these
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findings to the lives of rural PWUDs and highlight the role of trauma as
a potent feature of the risk environment with lasting impact throughout
participants’ drug use trajectory.
Although the escalation of drug use during times of trauma in our
narratives most likely indicates that individuals were seeking relief
from emotional and physical pain, the resulting increase in risk beha-
vior demonstrates greater risk for overdose and infection. It remains
possible that depressive symptoms and a lack of regard for the amount
of drugs used represents a form of undeclared suicidality. Although
associations have been made between pain and suicidality (Fishbain
et al., 2014), the relationship of seeking relief from trauma with opioids
and its relationship to suicidality needs further study.
The association of prescription opioid use, either medically or
nonmedically, with subsequent opioid use has been well-described
(Grau et al., 2007; Lankenau et al., 2012; Mars et al., 2014; Rose et al.,
2018). Factors associated with prescription opioid initiation, misuse,
and overdose include potentially inappropriate opioid prescribing, such
as multiple prescribers and co-prescription of opioids and benzodiaze-
pines (Rose et al., 2019; Sun et al., 2017). The role of the over-pre-
scription of opioids as a feature of the urban risk environment has also
been well-studied (Ciccarone, 2018; Grau et al., 2007). Strong asso-
ciations exist among inappropriate opioid prescribing, risk for over-
dose, and all-cause mortality (Rose et al., 2018, 2019; Stopka et al.,
2017). Additionally, abrupt discontinuation of opioid prescriptions and
inadequate tapering is known to lead to transitions to heroin and fen-
tanyl use and elevated overdose risk (Brady et al., 2015; Mars et al.,
2014; Somerville et al., 2017; Mark and Parish, 2019). Our findings
extend these features of the risk environment to a rural setting, with
instances of opioid initiation following car accidents, athletic injuries,
wisdom tooth extraction, and back injuries. Participants reported re-
ceiving opioid prescriptions with large numbers of pills over long per-
iods of time (i.e., several months to years), which were then stopped
Fig. 3. Age at event curve for age of transition to injection among survey participants who have injected drugs in the past 30 days and contextual findings from
qualitative interviews in rural northern New England, 2018-2019. This figure combines an event curve for age of first drug injection from the survey sample who have
injected drugs in the past 30 days (N = 417) and adds context from in depth interviews of four individuals whose narratives represent a range of trajectories and
themes from initial use of opioids to injection.
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suddenly. These abrupt discontinuations were often associated with
being “red flagged” after someone reported they were misusing opioids
(Mark and Parish, 2019). Withdrawal symptoms led them to seek street
opioids with often devastating effects.
Our findings have several limitations. First, we focused on rural
communities along the Connecticut River Valley of northern New
England. Access to many OUD prevention and treatment resources is
limited in these communities (Stopka et al., 2019a,b), but expanding
research locations might have provided differing insights into different
populations of rural PWUD. Second, while our 22 in-depth interviews
reached thematic saturation, we only completed one to five interviews
in each community of focus. More nuanced understanding of local risk
environments might have been possible with additional data collection
in each of these sites. Third, while limited racial and gender diversity in
this study reflect the local population, it may not reflect experiences of
rural people of color or transgender populations. Fourth, our varied
perspectives (public health, medicine, nursing, addictions, and epide-
miology) influenced our coding, analysis, and interpretation of findings,
which could have been augmented by additional expertise.
Despite these limitations, normalization of drug use, trauma, and
abrupt discontinuation of opioid prescriptions characterize the risk
environment for opioid use disorder initiation and transition to injec-
tion use in rural northern New England. These findings can help to
inform interventions that incorporate a unified intervention approach
to addiction, trauma, mental health, and pain. The Hub and Spoke
model in Vermont provides a wide range of services to PWUD (Rawson
et al., 2019), and New Hampshire recently established treatment
Doorways across the state (Wickham, 2019). These care models aim to
offer effective treatment closer to home. Both systems are currently
focused on substance use treatment, while our findings indicate the
need for integrated mental health, substance use, and pain care. Greater
access to comprehensive treatment in rural areas is needed to address
the high prevalence of trauma, pain, and mental health comorbidities
among rural PWUD. Current services are focused on PWUD; however,
greater access to comprehensive health and social services and, in
particular, mental health services that address trauma, could prevent
substance use initiation or progression to injection. Future research that
examines these components of the rural structural risk environment and
its relationship to injection initiation is recommended.
5. Conclusions
Our findings elaborate on key features of the risk environment for
opioid initiation and transition to injection in rural northern New
England. The normalization of drug use in families and communities,
experience of trauma, and the prescription and then abrupt dis-
continuation of opioids have contributed to the current rural opioid
crisis. The normalization of drug use in participants’ families and
communities suggests that public health and clinical providers should
invest in effective family and community-level interventions in rural
communities. The extent and severity of traumatic experiences in our
rural sample highlights the importance of enhancing access to treat-
ment and harm reduction programs that focus on trauma-informed and
holistic models. Inappropriate opioid prescribing and tapering practices
in rural communities underscore the need for clinical practice im-
provement for opioid prescribing, tapering, and transition to medica-
tion for opioid use disorder. As part of a comprehensive system of in-
tegrated mental health, substance use, and pain care, interventions in
these areas will address the risk environment and might begin to heal
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